Kratom products; modifying certain definitions; removing certain packing and labeling requirements. Effective date.
SB 891 updates Oklahoma’s Kratom Consumer Protection Act by revising definitions and tightening product standards for kratom foods and dietary supplements. The bill defines key terms such as kratom leaf, kratom leaf extract, kratom product, total kratom alkaloids, independent testing laboratory, and vendor. It also clarifies that kratom products may not contain synthesized kratom alkaloids or metabolites, and it sets limits on alkaloid composition and residual solvents used in extraction.
The bill also changes labeling and sale requirements. It removes some prior packaging and labeling provisions while requiring labels to list ingredients, disclose the amount of total kratom alkaloids, mitragynine, and 7-hydroxymitragynine, identify the vendor, include age-restriction and safety warnings, and carry the FDA disclaimer that the product is not intended to diagnose, treat, cure, or prevent disease. Vendors must not sell kratom products to anyone under 18, and they must provide independent laboratory test results to the State Department of Health upon request. The act takes effect November 1, 2025.
SB 891 amends Title 63 of the Oklahoma Statutes, specifically Sections 1-1432.2 and 1-1432.4 of the Oklahoma Kratom Consumer Protection Act. It narrows what qualifies as a lawful kratom product, prohibits certain adulterated or synthesized products, and imposes updated labeling, age-verification, and testing-disclosure obligations on vendors, manufacturers, and distributors. The bill affects kratom retailers and other businesses that sell or handle kratom products, while giving the State Department of Health a clearer enforcement and verification role.
The bill appears to have broad bipartisan support and little visible opposition in the recorded votes. It passed the Senate Health & Human Services Committee unanimously, cleared Senate floor votes overwhelmingly, and advanced through House committees with strong margins, including one committee vote with two dissenting votes and a House floor vote of 78-13. Overall, the voting pattern suggests general agreement with regulating kratom products more tightly while preserving lawful sales.
The main points of contention appear to center on how strictly kratom should be regulated and what product standards should apply. The bill’s restrictions on synthesized alkaloids, limits on 7-hydroxymitragynine, residual solvent standards, and expanded labeling requirements may be viewed by industry participants as burdensome, while supporters likely see them as consumer-protection measures. The few no votes in House committee and on the House floor suggest some lawmakers may have had concerns about regulatory scope, compliance costs, or the balance between consumer access and public health safeguards.